Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay

• Autorzy: Vogt U. , Falkiewicz B. , Bielawski K. , Bosse U. , Schlotter C.M.
• Języki publikacji: EN

Abstrakty

EN

A pilot study on relationships of selected molecular factors [erbB-1, erbB-2, erbB-3, and c-myc oncogene average gene copy numbers (AGCN); steroid receptors and pS2 gene expression; tumor cells' DNA values] to the ex vivo chemosensitivity of ovarian cancer in a modified adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA), was performed. Despite the relatively small number of patients, numerous correlations among the factors tested were found. Nevertheless, only c-myc gene dosage positively affected ex vivo chemosensitivity of tumors tested.

Słowa kluczowe

EN

ex vivo; antineoplastic agent; chemosensitivity; tumour cell; antitumour drug; ovarian cancer; oncogene; cancer; gene aberration

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2000
• Tom: 47
• Numer: 1
• Opis fizyczny: p.157-164

Twórcy

autor

Vogt U.

autor

Falkiewicz B.

autor

Bielawski K.

autor

Bosse U.

autor

Schlotter C.M.

Bibliografia

• 1. Andreotti, P.E., Linder, D., Hartmann, D.M., Cree, I.A., Pazzagli, M. & Bruckner, H.W. (1994) TCA-100 tumour chemosensitivity assay: Differences in sensitivity between cultured tumour cell lines and clinical studies. J. Biolumin. Chemilumin. 9, 373-378.
• 2. Andreotti, P.E., Cree, I.A., Kurbacher, C.M., Hartmann, D.M., Linder, D., Harel, G., Gleiberman, I., Caruso, P.A., Ricks, S.H., Untch, M., Sartori, C. & Bruckner, H.W. (l995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: Clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 55, 5276-5282.
• 3. Beckmann, A., Vogt, U., Huda, N., Znker, K.S. & Brandt, B.H. (1999) Direct-double-differential PCR for gene dosage quantification of c-myc. Clin. Chem. 45, 141-143.
• 4. Berns, E.M.J.J., Foekens, J.A., Van Staveren, I.L., Van Putten, W.L.J., De Koning, H.Y.W.C.M, Portengen, H. & Klijn, J.G.M. (1995) Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 159, 11-18.
• 5. Brandt, B., Vogt, U., Griwatz, C., Harms, F., Bosse, U. & Znker, K.S. (1994) Detection of amplified oncogenes by differential polymerase chain reaction; in Methods in DNA Amplification (Rolfs, A., Weber-Rolfs, I. & Finckh, U, eds.) pp. 55-64, Plenum Press, New York.
• 6. Brandt, B., Vogt, U., Harms, F., Bosse, U., Znker, K.S. & Assmann, G. (1995a) Double-differential PCR for gene dosage estimation of erbB oncogenes in benign and cancer tissues and comparison to cellular DNA content. Gene 159, 29-34.
• 7. Brandt, B., Vogt, U., Schlotter, C.M., Jackisch, C., Werkmeister, R., Thomas, M., Von Eiff, M., Bosse, U., Assmann, G. & Znker, K.S. (1995b) Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: Double-differential polymerase chain reaction (ddPCR) for clinical diagnosis. Gene 159, 35-42.
• 8. Cortazar, P. & Johnson, B.E. (1999) Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J. Clin. Oncol. 17, 1625-1631.
• 9. Cree, I.A. & Kurbacher, C.M. (1997) Individualizing chemotherapy for solid tumors is there any alternative? Anti-Cancer Drugs 8, 541- 548.
• 10. De Vita, V.T., Jr. (1997) Principles of cancer management: Chemotherapy; in Cancer: Principles and Practice of Oncology (De Vita, V.T., Jr., Hellman, S. & Rosenberg, S.A., eds.) pp. 333-347, Lippincott-Raven Publishers, Philadelphia.
• 11. Falkiewicz, B. & Vogt, U. (1999) In vitro prediction of cancer patients' response to chemotherapy; in Breast Cancer (Bonk, U. et al., eds.). Ullstein Medical Verlag Wiesbaden, Springer (in press).
• 12. Falkiewicz, B., Schlotter, C.M., Bosse, U., Bielawski, K., Podhajska, A.J. & Vogt, U. (1999) Chemosensitivity of primary human breast cancers in ATP-CVA assay in relationship to their oncogene status. 7 th International Symposium on Molecular Aspects ofChemotherapy, 8-11 September 1999, Gdansk, Poland. Abstract book, p. 94.
• 13. Gerhardt, R.T., Perras, J.P., Sevin, B.U., Petru, E., Ramos, R., Guerra, L. & Averette, H.E. (1991) Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay. Am. J. Obstet. Gynecol. 165, 245-255.
• 14. Kurbacher, C.M., Mallmann, P., Kurbacher, J.A., Hubner, H. & Krebs, D. (1996) Chemosensitivity testing in gynaecological oncology: Experiences with an ATP-bioluminescence assay. Geburtsh. Frauenheilk. 56, 70-78 (in German).
• 15. Kurbacher, C.M., Bruckner, H.W., Cree, I.A., Kurbacher, J.A., Wilhelm, L., Poch, G., Indefrei, D., Mallmann, P. & Andreotti, P.E. (1997) Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: Laboratory study and clinical pilot trial. Clin. Cancer Res. 3, 1527-1533.
• 16. Kurbacher, C.M., Cree, I.A., Bruckner, H.W., Brenne, U., Kurbacher, J.A., Mueller, K., Ackermann, T., Gilster, T.J., Wilhelm, L.M., Engel, H., Mallmann, P.K. & Andreotti, P.E. (1998) Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anti-Cancer Drugs 9, 51-57.
• 17. Kurbacher, C.M., Bruckner, H.W., Cree, I.A., Andreotti, P.A. & Janat, M.M. (1999) A prospective clinical trial on individualized chemotherapy for recurrent ovarian cancer selected by the ex vivo ATP tumor chemosensitivity assay. Proc. Am. Soc. Clin. Oncol. 18, 1384 (abstract).
• 18. Petty, R.D., Cree, I.A., Sutherland, L.A., Hunter, E.M., Lane, D.P., Preece, P.E. & Andreotti, P.E. (1994) Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem. Biophys. Res. Commun. 199, 264-270.
• 19. Ryan, K.M. & Birnie, G.D. (1996) Myc oncogenes: The enigmatic family. Biochem. J. 314, 713- 721.
• 20. Schlotter, C.M., Bosse, U., Falkiewicz, B., Bielawski, K. & Vogt, U. (1999) Correlation of erbB oncogene family gene dosages and erbB-2 expression to in vitro chemosensitivity of primary human breast cancers. Proc. Am. Soc. Clin. Oncol. 18, 409 (abstract).
• 21. Schwartz, G.N., Pendyala, L., Kindler, H., Meropol, N., Perez, R., Raghavan, D. & Creaven, P. (1998) The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Eur. J. Cancer34, 1543-1548.
• 22. Sevin, B.-U., Perras, J.P., Averette, H.E., Donato, D.M. & Penalver, M. (1993) Chemosensitivity testing in ovarian cancer. Cancer 71 (Suppl. 4), 1613-1620.
• 23. Sevin, B.-U. & Perras, J.P. (1997) Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer. Am. J. Obstet. Gynecol. 176, 759-766.
• 24. Untch, M., Sevin, B.U., Perras, J.P., Angioli, R., Baibl, A., Nguyen, H.N., Hightower, R.D. & Averette, H.E. (1992) Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro. Gynecol. Oncol. 47, 172-178.
• 25. Untch, M., Sevin, B.U., Perras, J.P., Angioli, R., Untch, A., Hightower, R.D., Koechli, O. & Averette, H.E. (1994) Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol. Oncol. 53, 44-49.
• 26. Vogt, U., Striehn, E., Bosse, U. & Klinke, F. (1998a) Is the combination of ATP cell viability chemosensitivity assay (ATP-CVA) and molecular prognostic factors able to detect NSCLC patients with good or poor response to chemotherapy? Thorac Cardiovasc. Surg. 46 (suppl. 1), 225 (abstract).
• 27. Vogt, U., Bielawski, K., Schlotter, C.M., Bosse, U., Falkiewicz, B. & Podhajska, A.J. (1998b) Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. Gene 223, 375-380.
• 28. Vogt, U., Bielawski, K., Schlotter, C.M., Bosse, U., Podhajska, A.J. & Falkiewicz, B. (1999a) Relationship of c-myc and erbB oncogene family gene aberrations and other molecular factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay. 7th International Symposium on Molecular Aspects ofChemotherapy 8-11 September 1999, Gdansk, Poland. Abstract book, p. 95.
• 29. Vogt, U., Striehn, E., Bosse, U., Klinke, F. & Falkiewicz, B. (1999b) Lack of squamous cell lung carcinoma in vitro chemosensitivity to various drug regimens in the adenosine triphosphate cell viability chemosensitivity assay. Acta Biochim. Polon. 46, 299-302.
• 30. Zabel, M., Kaczmarek, A., Lukianow, R., Ramlau, R. & Gorny, A. (1992) Testowanie wrazliwosci komorek nowotworowych na cytostatyki w warunkach hodowli komorkowej. Nowotwory 42, 187-192 (in Polish).
• 31. Zabel, M., Kaczmarek, A., Rozmiarek, A. & Markowska, J. (1997) Test wrazliwosci komorek nowotworowych na cytostatyki in vitro, a efekt kliniczny. Wspolcz. Onkol. 2, 17-19 (in Polish).